Provided by Tiger Trade Technology Pte. Ltd.

Oric Pharmaceuticals Inc.

13.02
-0.4500-3.34%
Volume:568.03K
Turnover:7.50M
Market Cap:1.35B
PE:-9.64
High:13.62
Open:13.42
Low:12.97
Close:13.47
52wk High:14.93
52wk Low:7.23
Shares:103.52M
Float Shares:88.69M
Volume Ratio:0.85
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3513
EPS(LYR):-1.4747
ROE:-39.80%
ROA:-25.97%
PB:3.54
PE(LYR):-8.83

Loading ...

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

GlobeNewswire
·
Aug 04

Oric Pharmaceuticals Expands 2022 Inducement Equity Plan Share Pool by 1,100,000 Shares

Reuters
·
Jul 31

Oric Pharma Director Richard A. Heyman Disposes of 13,100 Common Shares Worth $157,462.00

Reuters
·
Jul 29

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

GlobeNewswire
·
Jul 20

Corrected-oric Pharmaceuticals: ‍entered Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Darolutamide for Himalayas-1 (not 'oric Pharmaceuticals Inc: Proposed Deal For')

THOMSON REUTERS
·
Jul 15

Oric Pharmaceuticals Signs Trial Collaboration with Bayer for Nubeqa Supply in Phase 3 Prostate Cancer Study

Reuters
·
Jul 15

Oric® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in Mcrpc Evaluating Rinzimetostat in Combination with Nubeqa® (darolutamide), Supported by Clinical Collaboration with Bayer

THOMSON REUTERS
·
Jul 15

Oric Pharmaceuticals Inc: Proposed Deal For

THOMSON REUTERS
·
Jul 15

Oric Pharmaceuticals Director Richard A. Heyman Sells 300 Shares for $3,600

Reuters
·
Jul 09

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 03

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS)

TIPRANKS
·
Jun 24

Oric Shareholders Approve Equity Plan, Governance Measures

TIPRANKS
·
Jun 23

Oric Pharmaceuticals shareholders approve amended, restated 2020 equity incentive plan

Reuters
·
Jun 23

Oric Pharmaceuticals Inc : Stifel Resumes Coverage With Buy Rating; Target Price $14

THOMSON REUTERS
·
Jun 12

Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE)

TIPRANKS
·
Jun 11

Analyst Reiterates Buy on ORIC as Share Price Pullback Creates Opportunity; $25 Price Target Maintained

TIPRANKS
·
Jun 08

Oric Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 08

Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 06

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 06

Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT), Tactile Systems Technology (TCMD) and Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Jun 03